114P Preliminary results of the “Blue Sky Radiomics” study on stage III NSCLC patients treated with chemo-radiation and consolidation immunotherapy

One of the primary endpoints of this study is to assess the prognostic power of Signature 0, a radiomics signature originally developed for predicting survival in patients undergoing chemoradiotherapy (CRT), in patients receiving consolidation immunotherapy after CRT. Here we present a preliminary analysis on the discriminative power of radiomics features for the potential implementation of Signature 0 in immunotherapy.